MedTrace Logo

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

NCT02886702 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 855

Last updated 2018-08-29

Study results available
· View outcomes & findings →

Summary

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

Conditions

Interventions

DRUG

Tazarotene Cream 0.05%

Tazarotene Cream 0.05% to cover only the lesions with a thin film.

DRUG

TAZORAC® (tazarotene) Cream 0.05%

TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.

DRUG

Placebo

Placebo (vehicle of the test product) to cover only the lesions with a thin film.

Sponsors & Collaborators

  • Fougera Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Angela C. Kaplan · Fougera Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-19
Primary Completion
2017-08-02
Completion
2017-08-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02886702 on ClinicalTrials.gov